Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool August 31, 2011 Brian Orelli	Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease.
The Motley Fool October 18, 2011 Evan Niu	Halozyme Therapeutics Shares Surged: What You Need to Know Shares of Halozyme Therapeutics are surging by as much as 22.5% today on news that, together with partner Roche Holding, the company has reported positive results from a trial study regarding one of its drugs.
The Motley Fool November 24, 2010 Sean Williams	ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags.
The Motley Fool December 11, 2006 Brian Lawler	Roche's Early Present to Halozyme Assuming it works, Enhanze may be a platform technology that could be applied across a wide range of injected products. Roche isn't exactly betting the farm on its success, though, with only $20 million of guaranteed up-front money. Investors, take note.
The Motley Fool October 22, 2010 Brian Orelli	No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further.
The Motley Fool July 16, 2008 Brian Lawler	A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size.
The Motley Fool April 30, 2008 Brian Lawler	ViroPharma: Risky and Exciting Solid lead drug, meet promising pipeline candidate.
The Motley Fool August 5, 2009 Brian Orelli	The Cash Cow Is Out of Milk ViroPharma has milked its antibiotic Vancocin, which it bought from Eli Lilly in 2004, pretty well, but it looks like the cash cow is finally running dry.
The Motley Fool February 9, 2009 Brian Orelli	ViroPharma Cut in Half ViroPharma's phase 3 drug, maribavir, failed to show an effect in reducing cytomegalovirus (CMV) disease in stem cell transplant patients, and the stock gets axed in half.
The Motley Fool January 9, 2007 Brian Lawler	ViroPharma's Healthy Sales Guidance The coming year looks like another strong one for the drug developer. This small-cap pharmaceutical stock is worth taking a look at just for its cheap valuation.
The Motley Fool December 3, 2009 Brian Orelli	I Love This Industry With double-digit gains, how could you not love the biotech industry?
The Motley Fool November 3, 2006 Brian Lawler	Nothing's Wrong With ViroPharma Despite potential generic competition on the horizon, the company is going strong. Vancocin's fate will determine how well shares of ViroPharma perform in the near future.
The Motley Fool September 26, 2007 Brian Orelli	4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies...
The Motley Fool September 27, 2007 Brian Lawler	ViroPharma's Good Bad News The prospects for ViroPharma's HCV-796 darkened significantly after the company reported troubling clinical results, however, there's still hope for the compound. Investors, take note.
Chemistry World November 4, 2015 Phillip Broadwith	Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema.
Chemistry World November 11, 2013 Phillip Broadwith	Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke.
The Motley Fool February 26, 2007 Rich Duprey	Foolish Forecast: Getting Indigestion With ViroPharma The small-cap pharmaceutical will report its fourth-quarter 2006 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool May 29, 2009 Brian Orelli	The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin.
The Motley Fool September 29, 2006 Brian Lawler	The Long Road Ahead for ViroPharma Faced with the threat of generic competition, the company focuses its efforts on a new drug. ViroPharma investors should watch intently.
The Motley Fool May 7, 2007 Brian Lawler	ViroPharma Victorious A strong first quarter helps the pharmaceutical storm into 2007. Investors, take note.
The Motley Fool February 28, 2008 Brian Lawler	ViroPharma in Check Sales of its antibiotic are slowing down, but there is a promising drug in its pipeline.
The Motley Fool November 27, 2009 Brian Orelli	Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first.
The Motley Fool August 10, 2007 Brian Lawler	ViroPharma Whacked by Data Shares of ViroPharma fall after safety issues come to light with one of its drugs. A phase 2 study of their hepatitis C antiviral medication has been halted, with only a slim chance of starting up again.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool August 6, 2007 Brian Lawler	Don't Discount ViroPharma The exciting biopharma announces its second-quarter financial results. Considering that its lead drug is highly profitable and has two strong pipeline candidates in development, shares of ViroPharma don't look expensive.
The Motley Fool November 21, 2007 Brian Lawler	Black Friday Bargain Stock: ViroPharma Is ViroPharma a good value right now? With competition worries out of the way, and a strong and growing cash flow, it won't take much success for value investors to be rewarded.
The Motley Fool October 30, 2007 Brian Lawler	ViroPharma Gets No Respect The drugmaker announces third-quarter results; sales of its only marketed drug, antibiotic treatment Vancocin, fell due to a higher level of wholesaler stocking. Investors, take note.
The Motley Fool July 9, 2008 Brian Lawler	ViroPharma Makes Its Case Rather than taking the more traditional route, ViroPharma has taken steps to try to make it significantly harder than normal for a generic-drug maker to attack its lead drug, Vancocin.
The Motley Fool April 17, 2008 Brian Lawler	The End for (Another) Hepatitis C Drug Candidate ViroPharma stops development of its compound after data showed it may hurt the liver.
The Motley Fool March 2, 2007 Brian Lawler	Veering ViroPharma The drugmaker announces healthier fourth-quarter financial results. But investors take note: ViroPharma's product could have a formidable competitor on the market in 2008.
The Motley Fool June 13, 2007 Brian Lawler	ViroPharma Is on Its Way ViroPharma completes preliminary enrollment in a study of one of its drug candidates. Investors, take note.
The Motley Fool July 20, 2007 Brian Orelli	Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports.
The Motley Fool September 23, 2011 Brian Orelli	Matching Supply and Demand Is Easier Said Than Done Pac Bio cuts its workforce due to lower-than-expected demand.
The Motley Fool October 19, 2007 Brian Orelli	Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls.